Morgan Stanley Starts Prime Medicine (PRME) at Equalweight
Tweet
Share
E-mailGet Alerts PRME Hot Sheet
Price: $3.09 -2.52%
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison initiates coverage on Prime Medicine (NASDAQ: PRME) with a Equalweight rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Prime Medicine click here. For more ratings news on Prime Medicine click here.
Shares of Prime Medicine closed at $21.12 yesterday.
You May Also Be Interested In
- Prime Drink Group Provides Bi-Weekly MCTO Status Report
- Leerink Starts Ligand Pharma (LGND) at Outperform
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
